Feng Iris, Kurlansky Paul A, Zhao Yanling, Patel Krushang, Moroi Morgan K, Vinogradsky Alice V, Latif Farhana, Sayer Gabriel, Uriel Nir, Naka Yoshifumi, Takeda Koji
Division of Cardiac Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, New York.
Division of Cardiac Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, New York; Center of Innovation and Outcomes Research, Department of Surgery, Columbia University, New York, New York.
J Heart Lung Transplant. 2025 Jan;44(1):11-21. doi: 10.1016/j.healun.2024.08.020. Epub 2024 Sep 6.
Since United Network for Organ Sharing (UNOS) revised their heart allocation policy in 2018, usage of veno-arterial extracorporeal life support (VA-ECLS) has dramatically increased as a bridge to transplant. This study investigated outcomes of VA-ECLS patients bridged to simultaneous heart-kidney transplant (SHK) in the new policy era.
This study included 774 adult patients from the UNOS database who received SHK between 10/18/18 and 12/31/21 and compared patients bridged to transplant on VA-ECLS (n = 50) with those not bridged (n = 724).
At baseline, SHK recipients bridged from VA-ECLS were younger (50.5 vs 58.0 years, p = 0.007), had higher estimated glomerular filtration rate (eGFR) at time of transplant (47.6 vs 30.1, p < 0.001), and spent fewer days on the waitlist (7.0 vs 33.5 days, p < 0.001). In the perioperative period, VA-ECLS was associated with higher rates of temporary dialysis (56.0% vs 28.0%, p < 0.001) but similar 2-year cumulative incidence of chronic dialysis (7.5% vs 5.4%, p = 0.800) and renal allograft failure (12.0% vs 8.1%, p = 0.500) compared to non-ECLS cohort. However, VA-ECLS patients had decreased survival to discharge (76.0% vs 92.7%, p < 0.001) and 2-year post-transplant survival (71.7% vs 83.0%, p = 0.004), as well as greater 2-year cumulative incidence of cardiac allograft failure (10.0% vs 2.7%, p = 0.002). Multivariable analyses found VA-ECLS at time of transplant to be independently associated with 2-year post-transplant mortality (HR [95% CI]: 3.40 [1.66-6.96], p = 0.001) and cardiac allograft failure (sub-distribution hazard ratio [SHR] [95% CI]: 8.51 [2.77-26.09], p < 0.001).
Under the new allocation policy, patients bridged to SHK from VA-ECLS displayed greater early mortality and cardiac allograft failure but similar renal outcomes compared to non-ECLS counterparts.
自器官共享联合网络(UNOS)在2018年修订其心脏分配政策以来,静脉-动脉体外膜肺氧合(VA-ECLS)作为移植桥梁的使用量急剧增加。本研究调查了在新政策时代接受同期心脏-肾脏移植(SHK)的VA-ECLS患者的结局。
本研究纳入了UNOS数据库中774例在2018年10月18日至2021年12月31日期间接受SHK的成年患者,并将接受VA-ECLS作为移植桥梁的患者(n = 50)与未接受VA-ECLS的患者(n = 724)进行比较。
在基线时,从VA-ECLS过渡到SHK的受者更年轻(50.5岁对58.0岁,p = 0.007),移植时的估计肾小球滤过率(eGFR)更高(47.6对30.1,p < 0.001),且在等待名单上花费的天数更少(7.0天对33.5天,p < 0.001)。在围手术期,VA-ECLS与更高的临时透析率相关(56.0%对28.0%,p < 0.001),但与非ECLS队列相比,慢性透析的2年累积发生率(7.5%对5.4%,p = 0.800)和肾移植失败率(12.0%对8.1%,p = 0.500)相似。然而,VA-ECLS患者出院生存率降低(76.0%对92.7%,p < 0.001),移植后2年生存率降低(71.7%对83.0%,p = 0.004),且心脏移植失败的2年累积发生率更高(10.0%对2.7%,p = 0.002)。多变量分析发现,移植时使用VA-ECLS与移植后2年死亡率(HR [95% CI]:3.40 [1.66 - 6.96],p = 0.001)和心脏移植失败(亚组分布风险比[SHR] [95% CI]:8.51 [2.77 - 26.09],p < 0.001)独立相关。
在新的分配政策下,与非ECLS患者相比,从VA-ECLS过渡到SHK的患者早期死亡率和心脏移植失败率更高,但肾脏结局相似。